Yüklüyor......
Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response
BACKGROUND: Poor drug response of sorafenib is a major challenge which reduces clinical benefit of renal cell carcinoma (RCC) patients. It is therefore of great clinical significance to elucidate the underlying mechanism to restore the therapeutic response to sorafenib. METHODS: Angiopoietin-like pr...
Kaydedildi:
| Yayımlandı: | Br J Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group UK
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6134083/ https://ncbi.nlm.nih.gov/pubmed/30033448 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0189-4 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|